Question 1

What is Onasemnogene abeparvovec?

Accepted Answer

Onasemnogene abeparvovec is a Other.

Question 2

How often does Onasemnogene abeparvovec appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Onasemnogene abeparvovec first tracked by Ergen?

Accepted Answer

First tracked on Dec 20, 2025.

Question 4

When was Onasemnogene abeparvovec last mentioned in news?

Accepted Answer

Last active on Dec 21, 2025.

Question 5

What is Onasemnogene abeparvovec's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Onasemnogene abeparvovec in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Onasemnogene abeparvovec?

Accepted Answer

UAE Approves Itvisma Gene Therapy (Dec 20, 2025, 6 articles).

Question 8

How did the "UAE Approves Itvisma Gene Therapy" event impact Onasemnogene abeparvovec?

Accepted Answer

Onasemnogene abeparvovec (onasemnogene abeparvovec) is the gene therapy approved by the United Arab Emirates — Emirates Drug Establishment to treat spinal muscular atrophy, targeting the genetic cause of the disease and improving patients' motor functions.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.